Activated protein C in sepsis

This publication has 76 references indexed in Scilit:

• NEW INSIGHTS ON THE PATHOPHYSIOLOGIC STAGES OF SEVERE SEPSIS (TRANSLATION FROM PRIMATE MODELS TO VARIANTS OF SEVERE SEPSIS IN HUMANS).
  Shock, 2004
• The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): Role, methodology, and results*
  Critical Care Medicine, 2003
• EARLY CONTROL OF THE FIRST STAGE OF THE RESPONSE TO LD100 E.COLI MAY OPTIMIZE THE THERAPEUTIC EFFECT OF ACTIVATED PROTEIN C.
  Shock, 2003
• Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis
  Thrombosis and Haemostasis, 2003
• A DEBATE ON THE SUBJECT “ARE SIRS AND MODS IMPORTANT IN THE CLINICAL EVALUATION OF PATIENTS?”
  Shock, 2000
• Gabexate mesilate, a synthetic protease inhibitor, attenuates endotoxin-induced pulmonary vascular injury by inhibiting tumor necrosis factor production by monocytes
  Critical Care Medicine, 1996
• Plasma levels of granulocyte elastase‐α₁‐proteinase inhibitor complex in patients with disseminated intravascular coagulation: Pathophysiologic implications
  American Journal of Hematology, 1994
• Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon.
  Journal of Clinical Investigation, 1987
• Diagnostic efficacy of six plasma proteins in evaluating consumptive coagulopathies. Use of receiver operating characteristic curves to compare antithrombin III, plasminogen, alpha 2-plasmin inhibitor, fibronectin, prothrombin, and protein C
  Archives of internal medicine (1960), 1986
• Modulation of endothelial cell hemostatic properties by tumor necrosis factor.
  The Journal of Experimental Medicine, 1986